Interferons, immunity and cancer immunoediting
The DOI matches its Crossref record; 118 of the 119 references it cites were found in a registry or an index.
Abstract
A clear picture of the dynamic relationship between the host immune system and cancer is emerging as the cells and molecules that participate in naturally occurring antitumour immune responses are being identified. The interferons (IFNs) - that is, the type I IFNs (IFNalpha and IFNbeta) and type II IFN (IFNgamma) - have emerged as central coordinators of tumour-immune-system interactions. Indeed, the decade-old finding that IFNgamma has a pivotal role in promoting antitumour responses became the focus for a renewed interest in the largely abandoned concept of cancer immunosurveillance. More recently, type I IFNs have been found to have distinct functions in this process. In this Review, we discuss the roles of the IFNs, not only in cancer immunosurveillance but also in the broader process of cancer immunoediting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a cytokine which promotes increased tumour immunogenicity and often used to assess T-cell activation31”
From Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis (2016) · cites this paper as [31]
Citations
Cites
1 retracted
Urisman, A., Molinaro, R. J., Fischer, N., Plummer, S. J., Casey, G., Klein, E. A., Malathi, K., Magi-Galluzzi, C., Tubbs, R. R., Ganem, D., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020025 · Cited by 577 · cited 1×
“However, it remains unclear whether the tumour-suppressor functions of RNaseL depend on IFN”
BackgroundRetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“Using a combination of histological and gene-expression analyses, Galon et al”
MethodCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Self-citationCancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249 · cited 1×
“These pathways coordinately defend cells from the oncogenic and/or genotoxic stimuli that can lead to malignant transformatio”
BackgroundHOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932 · cited 1×
“Detailed reviews of IFN biology have been published elsewher”
BackgroundSelf-citationMechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Self-citationThe Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citation
Research works printed but not linked: 1
- Yang, J., Murphy, T. L., Ouyang, W. & Murphy, K. M. Induction of interferon-γ production in TH1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur. J. Immunol. 29, 548–555 (1999). · DOI · Paper page
Cited by
Items 601–700 of 1,002
Cox, M. C., Battella, S., Scaleia, R. L., Pelliccia, S., Napoli, A. D., Porzia, A., Cecere, F., Alma, E., Zingoni, A., Mainiero, F., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.990773 · Cited by 42
“NK cells are endowed with cytotoxic activity and with the capability to promptly produce cytokines and chemokines.(19,38) A considerably higher frequency of cells expressing the cytotoxic granule marker Granzyme B (GrzB) characterized CD56, CD56 and CD16C NK cell populations in patients’ PBMC (Fig.”
BackgroundDeng, J., Liu, X., Rong, L., Chen, N., Li, X., Yang, W. C., Lu, Y., Yan, X., Qin, C., Zhang, L., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4340 · Cited by 46
Vlková, V., Štěpánek, I., Hrušková, V., Šenigl, F., Mayerová, V., Šrámek, M., Šímová, J., Bieblová, J., Indrová, M., Hejhal, T., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2222 · Cited by 39
“IFNγ is a cytokine with pleiotropic effects on tumour cells, which is also considered as a crucial mediator of effective antitumour immunity displaying direct impacts on tumour cells [22].”
BackgroundHan, H., Yang, X., Pandiyan, K., & Liang, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075136 · Cited by 46
“It is well-known that IFN signaling plays a vital role in recognition and elimination of cancer cells, thus promoting antitumor responses and protecting the host against the development of cancer [44].”
BackgroundDing, Y., Seow, S. V., Huang, C. H., Liew, L. M., Lim, Y. C., Kuo, I.-C., & Chua, K. Y. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03099.x · Cited by 41
Cell intrinsic & extrinsic factors in cervical carcinogenesis.
Jayshree, R. S., Adurthi, S., Maliekal, T. T., & Krishna, S. (2009) · PubMed · Cited by 40
Yu, X., Wang, H., Li, X., Guo, C., Yuan, F., Fisher, P. B., & Wang, X. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2142 · Cited by 40
GRIM-19: A master regulator of cytokine induced tumor suppression, metastasis and energy metabolism
Nallar, S. C., & Kalvakolanu, D. V. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.09.001 · Cited by 42
“IFNs act as sentinels to prevent and/or eliminate tumor development [1, 5].”
BackgroundMadapura, H. S., Nagy, N., Ujvári, D., Kallas, T., Kröhnke, M. C. L., Amu, S., Björkholm, M., Stenke, L., Mandal, P. K., McMurray, J. S., et al. (2017) · Oncogene · doi:10.1038/onc.2017.85 · Cited by 40
Awad, N. F. S., El-Hamid, M. I. A., Hashem, Y. M., Erfan, A. M., Abdelrahman, B. A., & Mahmoud, H. (2019) · Journal of Applied Microbiology · doi:10.1111/jam.14303 · Cited by 44
“Pro-inflammatory innate cytokines such as IL-1b, IL-6, IFN-c and IFN-b are important immunomodulators linking the innate and adaptive arms of the immune response to coordinate the appropriate immune response to a pathogen (Dunn et al. 2006).”
BackgroundSaigí, M., Alburquerque-Béjar, J. J., & Sánchez‐Céspedes, M. (2019) · Oncogene · doi:10.1038/s41388-019-0855-x · Cited by 41
Tanaka, T., Masuda, A., Inoue, J., Hamada, T., Ikegawa, T., Toyama, H., Sofue, K., Shiomi, H., Sakai, A., Kobayashi, T., et al. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-022-01939-8 · Cited by 44
“The IFN-gamma is secreted by the activated effector T cells, such as CD4 and CD8 T cells [55].”
BackgroundRole of mast cells in colorectal cancer development, the jury is still out
Heijmans, J., Büller, N. V. J. A., Muncan, V., & van den Brink, G. R. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.12.001 · Cited by 40
Meng, G., Mao, X., Xu, C., Yuan, D., Schnurr, M. M., & Wei, J. (2013) · International Journal of Cancer · doi:10.1002/ijc.28416 · Cited by 48
“IFNs are central coordinators of interactions between tumors and the immune system.(27) In contrast to IFN-g, which is limited to certain immune cell populations, type I IFNs can also be produced by tumor cells upon RIG-I activation.”
BackgroundhCAF1/CNOT7 regulates interferon signalling by targeting STAT1
Chapat, C., Kolytcheff, C., Romancer, M. L., Auboeuf, D., de la Grange, P., Chettab, K., Sentis, S., & Corbo, L. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.11 · Cited by 43
“The innate immune system is genetically programmed to rapidly detect and respond to infection by viruses or other pathogens and to play a key role in immune surveillance of tumours (Dunn et al , 2006).”
Targeting STING: From antiviral immunity to treat osteoporosis
Gao, Z., Gao, Z., Zhang, H., Hou, S., Zhou, Y., & Liu, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1095577 · Cited by 44
“Type I interferons can play a biological role in antiviral and immunomodulatory, inhibiting specific cell growth and proliferation and killing tumor cells (58, 59).”
BackgroundZhen, W., Luo, T., Wang, Z., Jiang, X., Yuan, E., Weichselbaum, R. R., & Lin, W. (2023) · Small · doi:10.1002/smll.202305440 · Cited by 39
Ho, J., Xirasagar, S., & Lin, H. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.10.008 · Cited by 39
“The risk of cancer is also elevated in immunosuppressed patients.(4,5) An association between cancer and herpes zoster has been recognized since 1955,(6) and it has been hypothesized that herpes zoster may be a predictor of a subsequent cancer diagnosis.”
BackgroundCrispene E, a cis-clerodane diterpene inhibits STAT3 dimerization in breast cancer cells
Mantaj, J., Rahman, S. M. A., Bokshi, B., Hasan, C. M., Jackson, P. J. M., Parsons, R. B., & Rahman, K. M. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob00052a · Cited by 40
Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
del Bano, J., Chames, P., Baty, D., & Kerfélec, B. (2015) · Antibodies · doi:10.3390/antib5010001 · Cited by 42
Silymarin suppressed lung cancer growth in mice via inhibiting myeloid-derived suppressor cells
Wu, T., Liu, W., Guo, W., & Zhu, X. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.04.039 · Cited by 39
Cancer immunotherapy in patients with preexisting autoimmune disorders
Donia, M., Pedersen, M., & Svane, I. M. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0595-8 · Cited by 40
“Given the strong evidences that functional adaptive immune responses can suppress cancer formation and development [13], an important question is whether therapeutically induced immune suppression for the treatment of autoimmunity may pose patients with AD at an unintended high risk of developing primary malignancies…”
BackgroundKalkavan, H., Sharma, P., Kasper, S., Helfrich, I., Pandyra, A. A., Gassa, A., Virchow, I., Flatz, L., Brandenburg, T., Namineni, S., et al. (2017) · Nature Communications · doi:10.1038/ncomms14447 · Cited by 46
“Three major mechanisms could be responsible for these effects: first, IFN-I can directly induce cell cycle arrest in cancer cells 60,61 ; second, IFN-I can trigger an antigen-specific antitumour immune response 4 ; and third, IFN-I can inhibit angiogenesis 37 .”
Integration of Nano drug-delivery System With Cancer Immunotherapy
Nakamura, T., & Harashima, H. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0071 · Cited by 40
Epstein barr virus encodes miRNAs to assist host immune escape
Li, W., He, C., Wu, J., Yang, D., & Yi, W. (2020) · Journal of Cancer · doi:10.7150/jca.42498 · Cited by 40
“lymphocytes, T lymphocytes and NK cells, so as to exert anti-viral and anti-tumor effects [79].”
BackgroundLi, Y., Song, Y., Li, P., Li, M., Wang, H., Xu, T., Yu, X., Yu, Y., Tai, Y., Chen, P., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000111 · Cited by 41
Liu, Q., Hao, C., Su, P., & Shi, J. (2009) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520902998679 · Cited by 39
“Transported via Golgi to the cell surface, the HLA class I-peptide complexes are screened by CTLs and trigger a potential immune response [2,3].”
BackgroundYi, Y., Wu, H., Gao, Q., He, H.-W., Li, Y., Cai, X., Wang, J., Zhou, J., Cheng, Y., Jin, J., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2487-z · Cited by 41
“The immunoblotting study showed that the metastatic potential of HCC cell lines did not correlate with IRF-1 or with IRF-2.”
InfluentialProtein Kinase C-θ Is Required for NK Cell Activation and In Vivo Control of Tumor Progression
Aguiló, J. I., Garaude, J., Pardo, J., Villalba, M., & Anel, A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801820 · Cited by 40
Wakita, D., Chamoto, K., Ohkuri, T., Narita, Y., Ashino, S., Sumida, K., Nishikawa, H., Shiku, H., Togashi, Y., Kitamura, H., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp144 · Cited by 39
Meng, Y., Mauceri, H. J., Khodarev, N. N., Darga, T. E., Pitroda, S. P., Beckett, M. A., Kufe, D. W., & Weichselbaum, R. R. (2010) · Molecular Therapy · doi:10.1038/mt.2010.18 · Cited by 41
Arens, R. (2012) · Advances in immunology · doi:10.1016/b978-0-12-396548-6.00009-3 · Cited by 38
High-Avidity T Cells Are Preferentially Tolerized in the Tumor Microenvironment
Zhu, Z., Singh, V., Watkins, S. K., Bronte, V., Shoe, J. L., Feigenbaum, L., & Hurwitz, A. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1123 · Cited by 38
“Loss ofMHC-I expression represents amajor impediment to successful immunotherapy and is a well-described mechanism of immune escape in many cancer types (35).”
BackgroundResultRetractedSearching for targets for the systemic therapy of mesothelioma
Stahel, R. A., Weder, W., Felley‐Bosco, E., Petrausch, U., Fontecedro, A. C., Schmitt-Opitz, I., & Peters, S. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv101 · Cited by 40
“IFN-α can promote the differentiation and activity of host immune cells and moreover correlates with generation of a durable antitumor response [83]; one clinical study exploring the efficacy of this cytokine in mesothelioma showed a response in ∼30% of patients when associated with chemotherapy, however with major to…”
BackgroundServais, F., Kirchmeyer, M., Hamdorf, M., Minoungou, N., Rose‐John, S., Kreis, S., Haan, C., & Behrmann, I. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.03.007 · Cited by 42
Plasmacytoid Dendritic Cell Impairment in Metastatic Melanoma by Lactic Acidosis
Monti, M., Vescovi, R., Consoli, F., Farina, D., Moratto, D., Berruti, A., Specchia, C., & Vermi, W. (2020) · Cancers · doi:10.3390/cancers12082085 · Cited by 38
Huang, H., Chang, C., Wang, C., & Lin, K. (2021) · Cells · doi:10.3390/cells10010067 · Cited by 43
Cancer Cells Hijack PRC2 to Modify Multiple Cytokine Pathways
Abou El Hassan, M., Huang, K., Eswara, M. B. K., Zhao, M., Song, L., Yu, T., Liu, Y., Liu, J. C., McCurdy, S., Ma, A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126466 · Cited by 38
Osteoimmunology: A View from the Bone
David, J. (2007) · Advances in immunology · doi:10.1016/s0065-2776(07)95005-1 · Cited by 45
Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors
Pallandre, J., Borg, C., Rognan, D., Boibessot, T., Luzet, V., Yesylevskyy, S. O., Ramseyer, C., & Pudlo, M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.08.054 · Cited by 38
Riley, C. H., Brimnes, M. K., Hansen, M., Jensen, M. K., Hasselbalch, H. C., Kjær, L., Straten, P. T., & Svane, I. M. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12687 · Cited by 38
“It has been studied intensely in vitro and has been shown to have stimulatory effects on T cells, natural killer cells (NK cells), and dendritic cells (DCs) (15, 16).”
BackgroundProtein Kinase C-θ (PKC-θ) in Natural Killer Cell Function and Anti-Tumor Immunity
Anel, A., Aguiló, J. I., Catalán, E., Garaude, J., Rathore, M. G., Pardo, J., & Villalba, M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00187 · Cited by 47
“Immuno-deficient mice develop more tumors than immuno-competent mice and clinical data support the notion that cancer immuno-surveillance also occurs in humans (Dunn et al., 2002, 2006; Aptsiauri et al., 2007).”
BackgroundHassanin, O., Abdallah, F., & Awad, A. (2013) · Veterinary Research Communications · doi:10.1007/s11259-013-9585-7 · Cited by 38
“One example, is type I interferon, IFN-α/β, which are important immunomodulators, linking the innate and adaptive arms of the immune response (Dunn et al. 2006).”
BackgroundToyoda, H., Ido, M., Nakanishi, K., Nakano, T., KAMIYA, H., Matsumine, A., Uchida, A., Mizutani, H., de Beaucoudrey, L., Vogt, G., et al. (2010) · Journal of Medical Genetics · doi:10.1136/jmg.2009.072108 · Cited by 44
“IFNg is involved in cancer elimination (immunosurveillance), as shown in mice.(32) IFNg, produced by T, NK, and NKT cells, has antitumour effects, including inhibiting spontaneous malignancy in AKR mice.”
BackgroundRoberts, B. K., Collado, G., & Barnes, B. J. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189061 · Cited by 38
Advances in the understanding of cancer immunotherapy
Shore, N. D. (2014) · British Journal of Urology · doi:10.1111/bju.12692 · Cited by 41
Targeting tumor tolerance: A new hope for pancreatic cancer therapy?
Delitto, D., Wallet, S. M., & Hughes, S. J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.008 · Cited by 42
Hao, Q., & Tang, H. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0579-y · Cited by 37
“Western blot analysis shows that NSCLC cell lines H441 and Calu-3 which were resistant to IFNγ/Smac mimetic co-treatment did not express STAT1 [27], a central molecular for IFNγ signaling (Fig.”
Chen, L., Ma, X., Dang, M., Dong, H., Hu, H., Su, X., Liu, W., Wang, Q., Mou, Y., & Teng, Z. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201900039 · Cited by 39
Immunological Prognostic Factors in Multiple Myeloma
Bębnowska, D., Hrynkiewicz, R., Grywalska, E., Pasiarski, M., Sosnowska‐Pasiarska, B., Smarz-Widelska, I., Góźdź, S. S., Roliński, J., & Niedźwiedzka‐Rystwej, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073587 · Cited by 39
NS5A protein of HCV enhances HBV replication and resistance to interferon response
Pan, Y., Wei, W., Kang, L., Wang, Z., Fang, J., Zhu, Y., & Wu, J. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.052 · Cited by 39
Dobrzanski, M. J., Rewers‐Felkins, K., Quinlin, I. S., Samad, K. A., Phillips, C. A., Robinson, W., Dobrzanski, D. J., & Wright, S. E. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.08.007 · Cited by 40
A Myeloid Cell Population Induced by Freund Adjuvant Suppresses T-cell−mediated Antitumor Immunity
Wang, Z., Jiang, J., Li, Z., Zhang, J., Wang, H., & Qin, Z. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181bed2ba · Cited by 37
Cancer Immunoediting of the NK Group 2D Ligand H60a
O’Sullivan, T. E., Dunn, G. P., LaCoursiere, D. Y., Schreiber, R. D., & Bui, J. D. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100413 · Cited by 37
Self-citationKatzman, P. J., Murphy, S. P., & Oble, D. A. (2011) · Pediatric and Developmental Pathology · doi:10.2350/10-09-0910-oa.1 · Cited by 37
Zhong, P., Nakata, K., Oyama, K., Higashijima, N., Sagara, A., Date, S., Luo, H., Hayashi, M., Kubo, A., Wu, C., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03060-5 · Cited by 38
“This raises a “chicken and egg” question regarding the upregulation of the MHC-I pathway by IFN-γ secreted from CD8 + T cells [45].”
BackgroundVaccine therapies for patients with glioblastoma
Sayegh, E. T., Oh, T., Fakurnejad, S., Bloch, O. G., & Parsa, A. T. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1502-6 · Cited by 38
“In support of this paradigm, immunosuppressed human subjects are more likely to develop oncovirus-related cancers, and tumor survival is inversely correlated with the extent of the intratumoral lymphocytic infiltrate [21].”
BackgroundTumor-Derived Microvesicles and the Cancer Microenvironment
Camussi, G., Deregibus, M. C., & Tetta, C. (2012) · Current Molecular Medicine · doi:10.2174/1566524011307010058 · Cited by 36
“This process, known as “cancer immuno-editing”, leads to the survival and uncontrolled proliferation of immune resistant cancer cells [83].”
The role of miR-183 cluster in immunity
Ichiyama, K., & Dong, C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.11.035 · Cited by 38
Herrera-Rios, D., Mughal, S. S., Teuber‐Hanselmann, S., Pierscianek, D., Sucker, A., Jansen, P., Schimming, T. T., Klode, J., REIFENBERGER, J., Felsberg, J., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00120 · Cited by 38
“As TILs represent also the major source for the secretion of inflammatory stimuli such as IFN-γ and TNF-α (4, 70), resulting in activation of lymphocytes and induction of PD-L1 expression, we analyzed this aspect also in our tissue specimens.”
BackgroundDroplet‐Based Combinatorial Assay for Cell Cytotoxicity and Cytokine Release Evaluation
Antona, S., Abele, T., Jahnke, K., Dreher, Y., Göpfrich, K., Platzman, I., & Spatz, J. P. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003479 · Cited by 36
Impact of Lipid Metabolism on Antitumor Immune Response
Mabrouk, N., Lecoeur, B., Bettaïeb, A., Paul, C., & Végran, F. (2022) · Cancers · doi:10.3390/cancers14071850 · Cited by 37
“This cancer immunosurveillance mechanism results from immune effector functions stimulated by recognition of stress ligands or antigens expressed on transformed cells [2].”
BackgroundTumor-Derived Microvesicles and the Cancer Microenvironment
Camussi, G., Deregibus, M. C., & Tetta, C. (2012) · Current Molecular Medicine · doi:10.2174/156652413804486304 · Cited by 43
IRF-1 Expression Is Essential for Natural Killer Cells to Suppress Metastasis
Ksienzyk, A., Neumann, B., Nandakumar, R., Finsterbusch, K., Grashoff, M., Zawatzky, R., Bernhardt, G., Häuser, H., & Kröger, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1565 · Cited by 41
“3 Introduction The immune surveillance hypothesis suggests that the immune system constantly monitors the organism, recognizes and eradicates abnormal or cancer cells (1).”
BackgroundSun, J., Schiffman, J. S., Raghunath, A., Tang, D. N., Chen, H., & Sharma, P. (2008) · PubMed Central · Cited by 41
Lesinski, G. B., Trefry, J. C., Brasdovich, M., Kondadasula, S. V., Sackey, K., Zimmerer, J. M., Chaudhury, A. R., Yu, L., Zhang, X., Crespin, T. R., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3092 · Cited by 41
“immune cells to recognize developing tumors (6).”
Zhuo, S., Zheng, L., Chen, J., Xie, S., Zhu, X., & Jiang, X. (2010) · Applied Physics Letters · doi:10.1063/1.3505762 · Cited by 35
Gosmann, C., Frazer, I. H., Mattarollo, S. R., & Blumenthal, A. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.201 · Cited by 35
“IFN-γ is central to the defense against many pathogens as well as to the immune control of cancer (Dunn et al., 2006).”
BackgroundNavarrete, M. A., Heining‐Mikesch, K., Schüler, F., Bertinetti‐Lapatki, C., Ihorst, G., Keppler‐Hafkemeyer, A., Dölken, G., & Veelken, H. (2010) · Blood · doi:10.1182/blood-2010-06-292342 · Cited by 35
“Median (range) age years 53 (30-78) 44 (30-60) 77 (56-78) 68 (57-75)”
Liu, W., Guo, W., Shen, L., Chen, Z., Luo, Q., Luo, X., Feng, G., Shu, Y., Gu, Y., Xu, Q., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.13812 · Cited by 35
“Th1 cells can repress tumor growth by secreting IFN-γ and supporting CTL function [25, 26].”
BackgroundPrzybytkowski, E., Davis, T., Hosny, A., Eismann, J., Matulonis, U. A., Wulf, G. M., & Nabavi, S. (2020) · BMC Cancer · doi:10.1186/s12885-020-6605-1 · Cited by 36
Xiao, J., Liang, J., Fan, J., Hou, P., Li, X., Zhang, H., Li, K., Bu, L., Li, P., He, M., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3656 · Cited by 37
Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer
Arina, A., Murillo, O., Dubrot, J., Azpilikueta, A., Alfaro, C., Perez‐Gracia, J. L., Bendandi, M., Palencia, B., Hervás‐Stubbs, S., & Melero, I. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.5.599 · Cited by 39
“Among all of these cytokines, IFN-γ plays the most important role in protection against cancer [16].”
BackgroundDraghiciu, O., Nijman, H. W., & Daemen, T. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/439053 · Cited by 37
“Although the host immune system is clearly capable of recognizing cancer cells [6], the ability to which it can control tumor growth remains very limited.”
BackgroundLansigan, F., Choi, J., & Foss, F. M. (2008) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2008.07.014 · Cited by 38
Bizama, C., Benavente, F. M., Salvatierra, E., Gutiérrez‐Moraga, A., Espinoza, J. A., Fernández, E. A., Roa, I. S., Mazzolini, G. D., Sagredo, E. A., Gidekel, M., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28405 · Cited by 35
“IFNg is a classic proinflammatory cytokine secreted by NK cells and CD8 T-cells that has been associated with different tumor lineages.(37,38) Among the large family of FZD receptors associated with the Wnt signaling pathway, we showed that FZD5 exhibited nearly 1,000-fold overexpression in gastric cancer samples.”
BackgroundWang, L., Liu, H., Chen, X., Zhang, M., Xie, K., & Ma, Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045491 · Cited by 37
“Previous studies have indicated that tumor prognosis is closely associated with immune escape by tumor cells [39].”
BackgroundHZE Radiation Non-Targeted Effects on the Microenvironment That Mediate Mammary Carcinogenesis
Barcellos-Hoff, M. H., & Mao, J.-H. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00057 · Cited by 34
“During initial clonal expansion, recognition of the stressed transformed cells by innate immune cells results in production of interferon-γ, a cytokine shown to play a key role in immunosurveillance against tumors (90, 91).”
BackgroundAi, R., Yan, T., Hao, Y., Jiang, L., Dan, H., Ji, N., Zeng, X. Y., Zhou, Y. J., & Chen, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.20312 · Cited by 37
“By cancer immunoediting, cancer cells can acquire resistance to the antitumor responses of IFNs (IFN-alpha and IFNbeta) in the continuously stimulating environment [71].”
BackgroundNew promises for manipulation of kynurenine pathway in cancer and neurological diseases
Costantino, G. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220802665734 · Cited by 38
“Targets (2009) 13(2) 251 the same mechanisms providing defence against foreign invaders may also contribute to defence against neoplastic cells was more recently instrumental in reconsideration of a very early hypothesis on the immunological protection of a host against tumor formation (immunosurveillance) [26] .”
BackgroundFighting cancers from within: augmenting tumor immunity with cytokine therapy
Pellegrini, M., Mak, T. W., & Ohashi, P. S. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.05.003 · Cited by 39
Minimal role for STAT1 in interleukin‐6 signaling and actions in the murine brain
Sanz, E., Hofer, M. J., Unzeta, M., & Campbell, I. L. (2007) · Glia · doi:10.1002/glia.20602 · Cited by 39
“STAT1 is a participant primarily in the type I and type II IFN signal transduction pathways (Dunn et al., 2006).”
BackgroundMismatch repair gene defects in sporadic colorectal cancer enhance immune surveillance
Scarpa, M., Ruffolo, C., Canal, F., Scarpa, M., Basato, S., Erroi, F., Fiorot, A., Dallagnese, L., Pozza, A., Porzionato, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6179 · Cited by 39
“A possible hypothesis is that in tumor with MMR defects by T-cells, macrophages, and natural killers, infiltration might be increased enhancing immune surveillance mechanisms [15].”
BackgroundMao, J., Cao, M., Zhang, F., Zhang, J., Duan, X., Lu, L., Yang, Z., Zhang, X., Zhu, W., Zhang, Q., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000164 · Cited by 35
“9 Therefore, a method to deliver IFN β into the tumor in a precise and persistent manner is highly desired.”
Interferon Signaling in Estrogen Receptor–positive Breast Cancer: A Revitalized Topic
Fu, X., Angelis, C. D., & Schiff, R. (2021) · Endocrinology · doi:10.1210/endocr/bqab235 · Cited by 37
The antitumor effects of interferon: A personal history
Gresser, I. (2007) · Biochimie · doi:10.1016/j.biochi.2007.03.005 · Cited by 34
The Role of STAT1 for Crosstalk between Fibroblasts and Colon Cancer Cells
Kaler, P., Owusu, B. Y., Augenlicht, L. H., & Klampfer, L. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00088 · Cited by 36
“STAT1 has been suggested to have tumor-suppressor properties (20) and expression of STAT1 suppressed the tumorigenicity of RAD-105 cells in vivo, which correlated with decreased expression of proangiogenic molecules such as bFGF, MMP-2, and MMP9 (21).”
BackgroundOxidative stress and inflammatory response biomarkers in dogs with mammary carcinoma
Machado, V. S., Crivellenti, L. Z., Bottari, N. B., Tonin, A. A., Pelinson, L. P., Borin‐Crivellenti, S., Santana, Á. E., Torbitz, V. D., Moresco, R. N., Duarte, T., et al. (2015) · Pathology - Research and Practice · doi:10.1016/j.prp.2015.06.011 · Cited by 39
Lack of FcRn Impairs Natural Killer Cell Development and Functions in the Tumor Microenvironment
Castaneda, D. C., Dhommée, C., Baranek, T., Dalloneau, E., Lajoie, L., Valayer, A., Arnoult, C., Demattei, M.-V., Fouquenet, D., Parent, C., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02259 · Cited by 34
“Similarly, the proportion of neutrophils was enhanced in the model of anti-TNF antibody immunization in FcRndeficientmice (46) and in othermodels (47).”
BackgroundStat1 Phosphorylation Determines Ras Oncogenicity by Regulating p27Kip1
Wang, S., Raven, J. F., Durbin, J. E., & Koromilas, A. E. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003476 · Cited by 40
“role in immune surveillance of tumors [3].”
BackgroundJachimowicz, R. D., Fracasso, G., Yazaki, P. J., Power, B. E., Borchmann, P., Engert, A., Hansen, H. P., Reiners, K. S., Madlener, M., von Strandmann, E. P., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1093 · Cited by 35
“However, onemajor restriction lies within tumor progression, as it may be viewed as an evolutionary process, leading to a selection of immuneresistant mutants (23).”
BackgroundAue, G., Sun, C., Liu, D., Park, J.-H., Pittaluga, S., Tian, X., Lee, E., Soto, S., Valdez, J., Marić, I., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800570 · Cited by 33
Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma
Rajani, K. R., Carlstrom, L. P., Parney, I. F., Johnson, A. J., Warrington, A. E., & Burns, T. C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00656 · Cited by 35
“IFN-γ, a type II interferon, can upregulate MHC class I and NKG2D expression to increase tumor recognition, inhibit development of Tregs, and increase the induction of cytotoxic T cells (159).”
BackgroundA High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer
Nederlof, I., Horlings, H. M., Curtis, C. N., & Kok, M. (2021) · Cancers · doi:10.3390/cancers13020316 · Cited by 34
Jin, Z., Song, M., Wang, J., Zhu, W., Sun, D., Liu, H., & Shi, G. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.944681 · Cited by 34
Charni, S., Aguilo, J. I., Garaude, J., de Bettignies, G., Jacquet, C., Hipskind, R. A., Singer, D. S., Anel, A., & Villalba, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803006 · Cited by 33
Wang, F., Xu, J., Zhu, Q., Qin, X., Cao, Y., Lou, J., Xu, Y., Xing, K., Li, Q., Xie, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079064 · Cited by 37
“There is a close relationship between tumor progression and dysregulation of cytokine expression, as seen for IFNG, TGF-b, and IL-17 [3,4].”
BackgroundSportès, C., & Hakim, F. T. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9063-9_55 · Cited by 35
Small-molecule therapeutics in rheumatoid arthritis: Scientific rationale, efficacy and safety
Meier, F. M. P., & McInnes, I. B. (2014) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2014.10.017 · Cited by 32
NKG2D ligand expression in pediatric brain tumors
Haberthur, K., Brennan, K., Hoglund, V. J., Balcaitis, S. D., Chinn, H. K., Davis, A. D., Kreuser, S. A., Winter, C., Leary, S. E. S., Deutsch, G. H., et al. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1250047 · Cited by 33
Metadata
- Authors
- Dunn, G. P., Koebel, C. M., & Schreiber, R. D.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Schreiber, Robert D.
- Venue
- Nature Reviews Immunology
- Published
- 2006-11
- Volume
- 6
- Issue
- 11
- Pages
- 836-848
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2052313621
- Cited by
- 1,617
- References
- 119
- Citations by year
- 2026: 33 · 2025: 51 · 2024: 87 · 2023: 104 · 2022: 84 · 2021: 94 · 2020: 93 · 2019: 73 · 2018: 85 · 2017: 74 · 2016: 93 · 2015: 100 · 2014: 100 · 2013: 79 · 2012: 76
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- interferon, type I interferon, interferon-gamma, cancer immunoediting, tumor surveillance, antitumor immunity, tumor-immune interactions, interferon-alpha, interferon-beta, cancer immunotherapy
- MeSH terms
- Animals, Humans, Immunity, Immunotherapy, Interferons, Neoplasms, Monitoring, Immunologic, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.